Targeting SHMTs and MTHFDs in Cancer: Attractive Opportunity for Anti-tumor Strategy

Overview

Journal Front Pharmacol

Date 2024 Mar 6

PMID 38444944

Authors

Xue Zhang

Zhenhua Wang

Affiliations

Soon will be listed here.

Abstract

One-carbon metabolism is a universal metabolic process that mediates the transfer of one-carbon units for purine and thymidine synthesis. One-carbon metabolism has been found to be dysregulated in various cancer types due to its role in production of purine and pyrimidine nucleotides, epigenetic program, and redox homeostasis. One-carbon metabolism is composed a network of one-carbon metabolic enzymes. Disturbing the expression and enzymatic activity of these one-carbon metabolic enzymes could lead to fluctuations of metabolites in the tumor microenvironment. Serine hydroxymethyltransferases (SHMTs) and methylenetetrahydrofolate dehydrogenases (MTHFDs) are gradually recognized as important one-carbon metabolic enzymes for regulating tumor initiation and development, representing potential therapeutic targets for anti-tumor strategies. In the review, we primarily focused on the role of SHMTs and MTHFDs in cancer. Several inhibitors targeting MTHFDs and SHMTs have exert its potential to decrease tumor burden and inhibit tumor proliferation, highlighting the potential of targeting one-carbon metabolic enzymes for anti-cancer strategies.

References

Ju H, Lu Y, Chen D, Zuo Z, Liu Z, Wu Q . Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst. 2018; 111(6):584-596. PMC: 6579745. DOI: 10.1093/jnci/djy160. View

Friso S, Udali S, De Santis D, Choi S . One-carbon metabolism and epigenetics. Mol Aspects Med. 2016; 54:28-36. DOI: 10.1016/j.mam.2016.11.007. View

Jin M, Lee W, You M, Jang A, Cheng S, Kim W . SHMT2 expression as a diagnostic and prognostic marker for thyroid cancer. Endocr Connect. 2021; 10(6):630-636. PMC: 8240706. DOI: 10.1530/EC-21-0135. View

Piskounova E, Agathocleous M, Murphy M, Hu Z, Huddlestun S, Zhao Z . Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015; 527(7577):186-91. PMC: 4644103. DOI: 10.1038/nature15726. View

Mo J, Gao Z, Zheng L, Yan M, Xue M, Xu J . Targeting mitochondrial one-carbon enzyme MTHFD2 together with pemetrexed confers therapeutic advantages in lung adenocarcinoma. Cell Death Discov. 2022; 8(1):307. PMC: 9256677. DOI: 10.1038/s41420-022-01098-y. View

Bonagas N, Gustafsson N, Henriksson M, Marttila P, Gustafsson R, Wiita E . Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. Nat Cancer. 2022; 3(2):156-172. PMC: 8885417. DOI: 10.1038/s43018-022-00331-y. View

Pikman Y, Ocasio-Martinez N, Alexe G, Dimitrov B, Kitara S, Diehl F . Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia. 2021; 36(2):348-360. PMC: 8807390. DOI: 10.1038/s41375-021-01361-8. View

Cuthbertson C, Arabzada Z, Bankhead 3rd A, Kyani A, Neamati N . A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight. ACS Pharmacol Transl Sci. 2021; 4(2):624-646. PMC: 8033767. DOI: 10.1021/acsptsci.0c00223. View

Zhu L, Liu X, Zhang W, Hu H, Wang Q, Xu K . MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder. BMC Cancer. 2022; 22(1):556. PMC: 9112551. DOI: 10.1186/s12885-022-09606-0. View

10.

Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

11.

Pan S, Fan M, Liu Z, Li X, Wang H . Serine, glycine and one‑carbon metabolism in cancer (Review). Int J Oncol. 2021; 58(2):158-170. PMC: 7864012. DOI: 10.3892/ijo.2020.5158. View

12.

Yan Y, Zhang D, Lei T, Zhao C, Han J, Cui J . MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2. Clin Exp Pharmacol Physiol. 2019; 46(10):928-936. DOI: 10.1111/1440-1681.13125. View

13.

Cui X, Cui Y, Du T, Jiang X, Song C, Zhang S . SHMT2 Drives the Progression of Colorectal Cancer by Regulating UHRF1 Expression. Can J Gastroenterol Hepatol. 2022; 2022:3758697. PMC: 8863481. DOI: 10.1155/2022/3758697. View

14.

Shi Y, Xu Y, Yao J, Yan C, Su H, Zhang X . MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling. J Cell Mol Med. 2021; 25(14):7013-7027. PMC: 8278097. DOI: 10.1111/jcmm.16715. View

15.

Yang X, Wang Z, Li X, Liu B, Liu M, Liu L . SHMT2 Desuccinylation by SIRT5 Drives Cancer Cell Proliferation. Cancer Res. 2017; 78(2):372-386. DOI: 10.1158/0008-5472.CAN-17-1912. View

16.

Li G, Wu J, Li L, Jiang P . p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage. Proc Natl Acad Sci U S A. 2021; 118(28). PMC: 8285905. DOI: 10.1073/pnas.2019822118. View

17.

Nilsson R, Jain M, Madhusudhan N, Gustafsson Sheppard N, Strittmatter L, Kampf C . Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014; 5:3128. PMC: 4106362. DOI: 10.1038/ncomms4128. View

18.

Kawai J, Ota M, Ohki H, Toki T, Suzuki M, Shimada T . Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold. ACS Med Chem Lett. 2019; 10(6):893-898. PMC: 6580548. DOI: 10.1021/acsmedchemlett.9b00069. View

19.

Achreja A, Yu T, Mittal A, Choppara S, Animasahun O, Nenwani M . Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer. Nat Metab. 2022; 4(9):1119-1137. DOI: 10.1038/s42255-022-00636-3. View

20.

Miyo M, Konno M, Colvin H, Nishida N, Koseki J, Kawamoto K . The importance of mitochondrial folate enzymes in human colorectal cancer. Oncol Rep. 2016; 37(1):417-425. DOI: 10.3892/or.2016.5264. View